Ophthalmic Drugs In-Depth Industrial and Market studies (Dry eye, Anti-glaucoma, Anti-allergy/inflammatory/infective, Retinal Drugs) - Global Analysis, Size, Share, Growth, Trends and Forecast, 2017 - 2018

Albany, New York, Feb 28, 2017

"Ophthalmic Drugs Market (Dry eye, Anti-glaucoma, Anti-allergy/inflammatory/infective, Retinal Drugs) - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2017 - 2018" The Report covers current Industries Trends, Worldwide Analysis, Global Forecast, Review, Share, Size, Growth, Effect.

Description-

The global ophthalmic drugs market is rapidly growing due to increasing prevalence of eye disorders such as glaucoma, dry eye diseases and retinal diseases. Changing lifestyle, improved medical infrastructure, technological changes, increase in healthcare spending and aging population is also supporting the growth of the ophthalmic drugs market. 

Glaucoma is the largest drugs segment in global ophthalmic drugs market. Some of the major drugs for glaucoma treatment are Lumigan, Combigan, Xalatan, Ganfort and Saflutan. Diquas, Hyalein and Restasis are the major drugs for dry eye diseases. The retinal drugs market includes Ozurdex, Macugen, Visudyne and Lucentis. Patanol/Pataday, Tobradex, Vigamox and Bepreve are major ocular anti-inflammatory drugs. The ophthalmic drugs market covers prescription based drugs, OTC drugs and pipeline drugs. This report forecasts future potential of all these drug markets and analyses drivers and opportunities, restraints and challenges, market trends, Porter’s forces, competitive landscape and company profiles of key players.

Get Sample Report With TOC @ http://www.researchmoz.us/enquiry.php?type=S&repid=186323

The report categorizes the global ophthalmic drugs market based on major eye disorders, treatment drugs and geography. The treatment drugs market comprises treatment of major eye disorders such as glaucoma, dry eye drugs, retinal diseases and ocular inflammatory diseases. The market is further segmented on the basis of prescription based drugs, OTC drugs and pipeline drugs in different eye disorder areas. In the segment of geographic analysis, the report identifies and analyses market sizes and forecast of North America, Europe, Asia Pacific and Rest of the World (RoW). North America region covers the scenario of the US. Europe region covers the scenario of France, Germany and the UK. Asia Pacific region highlights the scenario of India, China and Japan.

– Table of Content

Chapter 1 Preface 8

1.1 Report Description 8

1.2 Research Methodology 8

Chapter 2 Executive Summary 10

Chapter 3 Ophthalmic Drugs – Industry Analysis 11

3.1 Introduction 11

3.2 Market Drivers and Opportunities 11

3.2.1 Increasing prevalence of eye disorders 12

3.2.2 Global aging population 12

3.2.3 Rising government initiatives towards healthcare infrastructure in developing countries 13

3.2.4 Technological changes in drug delivery techniques 14

3.2.5 Increasing prevalence of lifestyle associated diseases 14

3.3 Restraints and Challenges 15

3.3.1 Lack of awareness among people regarding eye disorders 15

3.3.2 Drying pipeline of ophthalmic drugs 15

3.3.3 Patent expiration of blockbuster ophthalmic drugs 16

3.3.4 Absence of health insurance in developing countries 16

Chapter 4 Ophthalmic Drugs Market Trends 18

4.1 Increased focus on combination therapy 18

4.2 Increasing mergers and acquisitions contribute to the growth of ophthalmic drugs market 18

Chapter 5 Porter’s Five Force Analysis 20

5.1 Bargaining power of buyers 20

5.2 Bargaining power of suppliers 21

5.3 Threat of new entrants 21

5.4 Threat from substitutes 21

5.5 Degree of competition 21

Chapter 6 Global Market Size and Forecast 22

Chapter 7 Ophthalmic Drugs Market – Treatment Drugs 25

7.1 Dry eye drugs 25

7.1.1 Existing 25

7.1.2 Pipeline 26

7.2 Retinal drugs 27

7.2.1 Existing 27

7.2.2 Pipeline 28

7.3 Ophthalmic anti-allergy/ inflammatory/ infective drugs 29

7.3.1 Existing 29

7.3.2 Pipeline 30

7.4 Anti-glaucoma drugs 31

7.4.1 Existing 31

7.4.2 Pipeline 32

Chapter 8 Ophthalmic Drugs Market: Regional Analysis 34

8.1 Scenario in North America 34

8.1.1 Scenario in the US 36

8.2 Scenario in Europe 38

8.2.1 Scenario in France 41

8.2.2 Scenario in Germany 42

8.2.3 Scenario in the UK 44

8.3 Scenario in Asia Pacific 46

8.3.1 Scenario in India 49

8.3.2 Scenario in China 50

8.3.3 Scenario in Japan 52

Chapter 9 Prescription vs. Over the Counter Drugs 55

Chapter 10 Competitive Landscape 57

Chapter 11 Company Profiles 62

11.1 Santen Pharmaceutical 62

11.1.1 Overview 62

11.1.2 Products and segments 62

11.1.3 Financial Performance 62

11.2 Pfizer 63